Venetoclax-Obinutuzumab: CLL’s New Power Duo?

Phase 3 study on previously untreated chronic lymphocytic leukemia showed sustained PFS with venetoclax-obinutuzumab.
Medscape Medical News

source https://www.medscape.com/viewarticle/venetoclax-obinutuzumab-clls-new-power-duo-2024a1000ket?src=rss